

1 **Safety and Efficacy of Adjunctive Intra-arterial Tenecteplase**
2 **following Successful Thrombectomy in Patients with Large**
3 **Vessel Occlusion: Study Rationale and Design of A Phase 1/2**
4 **Randomized Clinical Trial**

5
6 Xianhua Hou^{1*}, MD, Jiacheng Huang^{2,3*}, MD, Changwei Guo^{2*}, MD, Li
7 Wang^{4*}, MD, Yuxuan He^{1*}, MD, Lin Chen¹, MD, Qu Liu¹, MD, Junhua
8 Wu¹, MD, Min Wu¹, MD, Yazhou Wu⁵, PhD, Thanh N. Nguyen⁶, MD,
9 Raul G. Nogueira⁷, MD, Duolao Wang⁸, PhD, Jeffrey L. Saver⁹, MD,
10 Wenjie Zi^{2#}, MD, Zhenhua Zhou^{1#}, MD

11
12 **Institutions**

13 1.Department of Neurology, Southwest Hospital, Army Medical
14 University, Chongqing, China;

15 2.Department of Neurology, Xinqiao Hospital, Army Medical University,
16 Chongqing, China;

17 3.Department of Neurology, The Second Affiliated Hospital of
18 Chongqing Medical University, Chongqing, China;

19 4.Department of Neurology, Zigong Third People's Hospital, Zigong,
20 Sichuan, China;

21 5.Department of Health Statistics, College of Preventive Medicine, Army
22 Medical University, Chongqing, China.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 6.Department of Neurology and Radiology, Boston Medical Center, USA;

24 7.UPMC Stroke Institute, Departments of Neurology and Neurosurgery,

25 University of Pittsburgh School of Medicine, PA, USA;

26 8.Global Health Trials Unit, Liverpool School of Tropical Medicine,

27 Liverpool, UK;

28 9.Department of Neurology and Comprehensive Stroke Center, David

29 Geffen School of Medicine, University of California, Los Angeles, CA,

30 USA.

31

32 * First co-authors.

33 # Co-corresponding authors.

34 Total words: 2282

35 Number of figures: 1

36

37 Corresponding authors:

38 Zhenhua Zhou, MD

39 Department of Neurology, Southwest Hospital, Army Medical University,

40 30 Gaotanyan Main St., Shapingba District, Chongqing 400038, China.

41 E-mail: exploiter001@126.com.

42

43 Wenjie Zi, MD

44 Department of Neurology, Xinqiao Hospital, Army Medical University,

45 No. 183 Xinqiao Main Street, Shapingba District, Chongqing 400038,

46 China

47 Email: ziwenjie1981@163.com

48

49 **Abstract**

50 **Background:** Adjunct intra-arterial thrombolysis has been shown to
51 potentially improve clinical outcomes in patients with large vessel
52 occlusion (LVO) stroke who have undergone successful endovascular
53 thrombectomy (EVT). Tenecteplase, known for its enhanced fibrin
54 specificity and extended activity duration, may be a better choice than
55 alteplase for intra-arterial thrombolysis. However, the optimal dose,
56 safety and efficacy of intra-arterial tenecteplase remain unclear.

57 **Objective:** To evaluate the optimal dose, safety and efficacy of
58 adjunctive intra-arterial tenecteplase following successful EVT in LVO
59 patients.

60 **Methods and design:** This study is a two-part, phase Ib/IIa, multicenter,
61 open-label, 14+8 dose-escalation (Part I) and dose-expansion (Part II)
62 trial conducted in China involving patients LVO patients who achieved
63 successful EVT (defined as the expanded Thrombolysis in Cerebral
64 Infarction [eTICI] grade of 2b50 or higher) within 24 hours of last known
65 well. In Part Ib, the dose escalation will be conducted in up to four tiers
66 of 14+8 patients, starting at 0.03125 mg/kg, to a planned maximum of
67 0.1875mg/kg, and the primary outcome is symptomatic intracranial
68 hemorrhage within 24 hours. In Part IIa, 157 patients will be randomized
69 among two selected safe doses and a placebo, and the primary outcome

70 will be the proportion of patients with nondisabled outcome (modified
71 Rankin Scale score of 0 to 1) at 90 days.

72 **Discussions:** This pivotal trial will provide important data on adjunctive
73 intra-arterial tenecteplase following successful EVT in patients with acute
74 ischemic stroke due to LVO and may support advance of treatment
75 standards.

76 **Trial registry number:** ChiCTR2300073787 and ChiCTR2400080624
77 (www.chictr.org.cn).

78 **Keywords:** Clinical trial, Tenecteplase, Mechanical thrombectomy,
79 Acute ischemic stroke, Large vessel occlusion

80

81

82

83

84

85

86

87 **Introduction**

88 Stroke is one of the leading causes of morbidity and mortality
89 worldwide.¹ Endovascular thrombectomy (EVT) is currently
90 recommended as the gold standard treatment for acute ischemic stroke
91 caused by large vessel occlusion (LVO).² However, a meta-analysis study
92 consisted of five randomized clinical trials indicated that two-thirds of
93 patients had disabled (modified Rankin Scale [mRS] 2-6) outcomes after
94 EVT despite successful reperfusion (defined as the extended
95 Thrombolysis In Cerebral Infarction [eTICI] grade of 2b50 or higher).^{3,4}
96 Already infarcted tissue present before the procedure, combined with
97 infarct expansion into areas lacking sufficient macro- and
98 microcirculatory reperfusion afterward, may lead to incomplete
99 functional recovery.⁵ Previous studies demonstrated that even when
100 successful reperfusion has been achieved after EVT, hypoperfusion is
101 common and this is associated with poor clinical outcomes.⁶ Preclinical
102 studies have shown that capillary occlusion, perivascular space
103 obstruction, or distal microembolism from a proximal thrombus may
104 cause incomplete reperfusion of the microcirculation and distal
105 vasculature.⁷

106 Targeting the mirco-thrombi, the Effect of Intra-arterial Alteplase vs
107 Placebo Following Successful Thrombectomy on Functional Outcomes in
108 Patients With Large Vessel Occlusion Acute Ischemic Stroke (CHOICE)

109 study showed that adjuvant intra-arterial thrombolysis after successful
110 reperfusion by EVT could improve excellent functional outcome at 90
111 days.⁸ However, this study was terminated prematurely with a resulting
112 limited sample size.

113 Tenecteplase is a modified form of alteplase, with a longer half-life
114 and greater fibrin specificity.^{9,10} After extensive exploration, preliminary
115 research established the optimal dose of intravenous TNK (0.25 mg/kg)
116 for thrombolysis therapy in stroke.¹¹ In the Tenecteplase versus Alteplase
117 before Thrombectomy for Ischemic Stroke (EXTEND-IA TNK) study,
118 administering tenecteplase (0.25 mg/kg) prior to thrombectomy resulted
119 in a higher rate of reperfusion and improved functional outcomes
120 compared to alteplase (0.9 mg/kg) in patients with LVO stroke.^{10,12}
121 Considering the advantages of tenecteplase, adjuvant intra-arterial
122 administration of tenecteplase may provide greater potential benefits for
123 patients with LVO stroke following successful reperfusion compared with
124 alteplase. However, the optimal dose, efficacy, and safety of intra-arterial
125 tenecteplase following successful reperfusion is unknown.

126 Therefore, we conduct a two-part, phase Ib/IIa, multicenter,
127 open-label, 14+8 dose-escalation (Part 1) and dose-expansion (Part 2)
128 trial to determine the most promising dose to advance to a pivotal trial of
129 intra-arterial tenecteplase following successful thrombectomy in patients
130 with acute ischemic stroke due to LVO within 24h of symptom onset.

131 **Methods**

132 **Study design**

133 The Safety and Efficacy of Adjunctive Intra-arterial Tenecteplase
134 following Successful Thrombectomy in Patients with Large Vessel
135 Occlusion (DATE) is an open-label, randomized, multicenter, Phase Ib/IIa
136 clinical trial designed to identify a dose of intra-arterial tenecteplase
137 following successful EVT in patients with acute ischemic stroke due to
138 LVO that shows sufficient evidence of safety and efficacy to advance to a
139 pivotal trial. In designing this protocol, we adhered to the SPIRIT
140 reporting guidelines¹³ for clarity and consistency. The DATE trial will be
141 divided into two parts: the first part (Phase Ib) is a pilot dose-escalation
142 safety study, and the second part (Phase IIa) is an exploratory study to
143 assess the safety and potential efficacy of adjunctive intra-arterial
144 tenecteplase after successful EVT in patients with LVO stroke at two
145 different doses. After the completion of Phase Ib, a data safety monitoring
146 board (DSMB) unblinded to study groups will select 2 doses (A or B) to
147 be tested in Phase IIa according to the initial safety results.

148 **Dose Escalation (Phase Ib):**

149 This is a dose escalation trial. During this phase, participants will
150 receive intra-arterial administration of increasing doses of tenecteplase
151 after successful EVT. Patients will be treated with up to 4 escalating dose

152 levels: 0.03125 mg/kg (1/8 *i.v* dose), 0.0625 mg/kg (1/4 *i.v* dose), 0.125
153 mg/kg (1/2 *i.v* dose), and 0.1875 mg/kg (3/4 *i.v* dose).

154 According to the Chinese Acute Anterior Circulatory Ischemic
155 Stroke Endovascular Treatment Registry Study, 13.8% of patients
156 experienced symptomatic intracranial hemorrhage (sICH) within 24 hours
157 of receiving EVT.¹⁴ Using sample sizes typical for dose escalation phase I
158 clinical trials^{15,16}, we will use a 14+8 design scheme with sICH
159 occurrence within 24 hours after EVT as the dose-limiting toxicity. At
160 each tier, 14 patients will initially be enrolled. If fewer than 2 of 14
161 subjects develop sICH, the trial will advance to the next tier. If 2 of the 14
162 develop sICH, 8 more patients will be enrolled at that dose. If 0-1 of the
163 additional 8 patients develops sICH, the trial will advance to the next tier.
164 If 2 of the additional 8 patients develops sICH or 3 of the first 14 develop
165 sICH, that dose will be deemed not tolerated and the immediately
166 preceding dose will be the estimated maximum tolerated dose. The chart
167 is shown in Figure 1.

168 **Dose Expansion (Phase IIa):**

169 Two doses (A and B) will be chosen by the DSMB and investigators
170 jointly according to the results in Phase Ib. In Phase II, a total of 157 new
171 patients will be enrolled, with 46 patients assigned to the dose A group,
172 46 patients assigned to the dose B group, and an additional 65 patients
173 allocated to the control group.

174 During this phase, 3 arms will be studied and patients will be
175 randomized with stratification allocation according to two strata: patient
176 age (<70 vs \geq 70 years), and admission NIHSS score (< 15 vs \geq 15), to
177 receive 1 of the 2 selected doses of tenecteplase, or to the control group in
178 a 1:1: $\sqrt{2}$ ratio, which in turn yields probabilities of assignment of 0.293,
179 0.293, and 0.414, respectively. Patients will be randomly assigned by
180 using a real-time internet-based system. This process is automated which
181 allows for concealment of the sequence of allocation.

182 **Objectives:** The primary objective of this study is to preliminarily assess
183 the safety and efficacy of adjunctive intra-arterial tenecteplase at different
184 doses following successful EVT in patients with acute ischemic stroke
185 due to LVO to determine the promising dose to advance to a pivotal trial.

186 **Outcome:** The study is designed to have two parts with different
187 outcomes.

188 **Dose Escalation (Phase Ib)**

189 • **Primary outcome:** The primary outcome is sICH within 24 hours.

190 • **Secondary outcome:**

191 1) 90-day modified mRS score 0-1 (%);

192 2) Proportion of patients with functional independence (mRS
193 score 0 to 2) at 90 days;

194 3) Level of disability (ordinal distribution of mRS scores) at 90
195 days;

196 4) Favorable shift in reperfusion on the eTICI score after
197 intra-arterial tenecteplase thrombolysis therapy. All post-EVT, pre-IA
198 and final post-IA final, angiograms will be scored at a core lab by
199 central and blinded reviewers using the eTICI and classified as
200 eTICI2b, eTICI2c, and eTICI3. The post treatment angiographies will
201 be scored using the eTICI and classified as “improved”, “worsened”
202 or “unchanged” with regard to the pre-IA infusion eTICI score.

203 5) The change from baseline of the NIHSS score to 5–7 days or
204 discharge if earlier;

205 6) EQ-5D-3L at 90 days;

206 7) Mortality within 90 days.

207 **Dose Expansion (Phase IIa):**

208 • **Primary outcome:** The primary outcome will be the proportion of
209 patients with a nondisabled outcome (mRS score of 0 or 1) at 90 (± 14)
210 days. Primary outcome assessments will be performed at 90 (± 14) days
211 by two independent, certified physicians who are blinded to the treatment
212 details. To maintain the reliability, accessibility, and traceability of the
213 mRS score, we will retain a video or audio records of the 90-day
214 follow-up for all patients. If video or audio recordings are unavailable,
215 outcomes will be determined in-person by certified local investigators,
216 who will be also unaware of the treatment assignment.

217 • **Secondary outcomes:**

- 218 1) Proportion of patients with functional independence (mRS score 0
219 to 2) at 90 days;
- 220 2) Level of disability (ordinal distribution of mRS scores) at 90 days;
- 221 3) Favorable shift in eTICI score after intra-arterial tenecteplase
222 thrombolysis therapy;
- 223 4) The change of the NIHSS score from baseline to 5–7 days or
224 discharge;
- 225 5) EQ-5D-3L at 90 days;
- 226 6) sICH rate within 24 hours;
- 227 7) Mortality within 90 days.

228 **Inclusion and exclusion criteria**

229 **Inclusion criteria**

- 230 1) Age ≥ 18 years;
- 231 2) Time from last known well within 24 hours;
- 232 3) Large vessel occlusive stroke in the anterior circulation confirmed
233 by computed tomography angiography/magnetic resonance angiography,
234 including intracranial segment of the internal carotid artery, first or
235 second segment of the middle cerebral artery;
- 236 4) Alberta Stroke Program Early CT Score (ASPECTS) ≥ 6 based on
237 non-contrast computed tomography;
- 238 5) National Institutes of Health Stroke Scale (NIHSS) score ≥ 6 ;
- 239 6) Successful endovascular thrombectomy (eTICI 2b-3);

240 7) Total pass numbers of thrombectomy procedure ≤ 3 ;

241 8) Written informed consent signed by patient or their family
242 member.

243 **Exclusion criteria**

244 1) NIHSS score ≥ 25 ;

245 2) Intracranial hemorrhage confirmed by computed tomography or
246 magnetic resonance imaging;

247 3) Treated by intravenous thrombolysis;

248 4) Prestroke mRS score ≥ 2 .

249 5) Intraprocedural digital subtraction angiography suggests vessel
250 penetration, dissection, or extravasation of contrast medium;

251 6) Pregnant or lactating patients;

252 7) Allergic to contrast agent or Tenecteplase;

253 8) Systolic pressure greater than 185 mmHg or diastolic pressure
254 greater than 110 mmHg despite blood pressure lowering treatment;

255 9) Genetic or acquired bleeding disposition with anticoagulation
256 factor deficiency or already taking oral anticoagulants within 48 hours
257 and INR > 1.7 ;

258 10) Blood glucose < 2.8 mmol/L (50 mg/dl) or > 22.2 mmol/L (400
259 mg/dl), platelets $< 90 \times 10^9/L$;

260 11) History of bleeding in the last 1 month (gastrointestinal and
261 urinary tract bleeding);

262 12) Patients on chronic hemodialysis and severe renal insufficiency
263 (glomerular filtration rate < 30 ml/min or blood creatinine > 220 µmol/L
264 [2.5mg/dl]);

265 13) Any terminal illness with a life expectancy of less than 6
266 months;

267 14) Intracranial aneurysm, arteriovenous malformation;

268 15) Brain tumor with occupying mass effect on imaging;

269 16) Puncture to reperfusion time > 90 min;

270 17) Current participation in another clinical trial;

271 18) Unlikely to be available for 90-day follow-up.

272 **Participating center eligibility**

273 To qualify for participation in this trial, study centers will be
274 mandated to have performed a minimum of 50 endovascular procedures
275 each year. Additionally, all neurointerventionists involved will be
276 required to have over five years of experience in cerebrovascular
277 interventions, along with a track record of having performed at least 30
278 cases of mechanical thrombectomy using stent retriever devices annually.

279 **Enrollment**

280 Before initiating any procedure, participants or their legally
281 authorized representatives will be provided with comprehensive oral and
282 written information regarding the study, encompassing its objectives,

283 potential risks, and anticipated benefits. Subsequently, they will be
284 required to give their informed consent.

285 All individuals who fulfill the specified eligibility criteria are
286 eligible for enrollment in the DATE clinical trial.

287 **Study Intervention**

288 Eligible patients assigned to the tenecteplase group will undergo an
289 infusion of intra-arterial tenecteplase with the assigned dose. This
290 infusion will be administered through a distal access catheter or
291 microcatheter positioned proximal to the initially occluded artery.
292 Patients allocated to the control group will terminate the procedure
293 without further intraarterial thrombolysis.

294 All enrolled patients should be monitored in the acute stroke unit
295 and can be admitted to the intensive care unit if necessary. All enrolled
296 patients will undergo standardized medical treatment management and
297 subsequent secondary preventive medication according to the Chinese
298 Guidelines for Endovascular Treatment of Acute ischemic Stroke 2018.¹⁷

299 **Blinding and masking**

300 Each participating site will allocate one or more physicians to
301 perform follow-up evaluations at 24-hour intervals, between five to seven
302 days post-treatment, or at the time of discharge if it occurs sooner, along
303 with a 90-day assessment. It is imperative that these physicians are not

304 involved in the subject's initial treatment to ensure their blinding to the
305 treatment assignment.

306 **Data safety monitoring board**

307 The independent Data and Safety Monitoring Committee (DSMB) is
308 responsible for reviewing the aggregated data and determining the study
309 safety endpoints. The DSMB regularly reviews the study data added
310 during the trial and advises the sponsor on the continued safety of the
311 subjects and those not yet included in the study. The DSMB advises on
312 the continued effectiveness and scientific value of the study.

313 **Sample size estimates**

314 *Dose Escalation (Phase Ib):*

315 The Endovascular Treatment for Acute Anterior Circulation
316 Ischemic Stroke registry in China showed that the incidence of sICH
317 within 24 hours after EVT was 13.8%.¹⁴ Based on this data, we designed
318 a 14+8 enrollment plan as follows:

319 1) 14 subjects will be included in the trial for the first time for each
320 dose;

321 2) If <2 DLT (dose limit toxicity) symptomatic intracranial
322 hemorrhages occur within 24 hours after EVT, the trial advances to the
323 next dose level;

324 3) If 2/14 DLT, then include 8 more people at the same dose;

325 4) If $2/14+0-1/8$ DLT (9.1% to 13.6%), proceed to the next dose
326 level;

327 5) If $2/14+2/8$ DLT (18.2%) or $3/14$ DLT, then this dose is deemed
328 unsafe and the prior lower dose is the MTD.

329 ***Dose Expansion (Phase IIa):***

330 In Phase IIa randomization will allocate to randomize 46 subjects
331 each into dose group A and dose group B, and 65 subjects into the control
332 group in a 1:1: $\sqrt{2}$ ratio. This approach is similar to the sample size
333 calculation method used in the APRIL study.¹⁸

334 **Statistical analyses**

335 Continuous variables will be summarized with the median, the
336 inter-quartile range, the minimum, and the maximum. Categorical
337 variables will be summarized with counts and percentages. Patient
338 compliance with eligibility criteria and treatment administration, major
339 protocol non-compliance, patient withdrawal and the reason for
340 withdrawal (e.g., adverse event, protocol non-compliance, lost to follow
341 up, failed to return, consent withdrawal, and other reasons) and
342 assignment to each analysis population will be summarized using
343 appropriate statistics by treatment arms.

344 The statistical results of outcome analyses will be provided with
345 point estimates of treatment differences with 95% confidence intervals
346 (CIs).

347 The primary outcome in both phase Ib and IIa will be analyzed using
348 generalized linear models from which a risk ratio with its 95% CI will be
349 estimated as a measurement of treatment effect. The secondary outcomes
350 and safety outcomes (binary, continuous and ordinal) will be analyzed
351 using generalized linear models. For non-normal continuous outcome, a
352 win ratio will be estimated as a measurement of treatment effect. A
353 pooled analysis that combines the phase Ib and phase IIa will be
354 performed as supportive analysis. The primary data analyses will adhere
355 to the intention-to-treat principle. Additionally, per-protocol analyses will
356 be conducted as supplementary analyses.

357 All statistical analyses will be described in detail in the statistical
358 analysis plan which will be finalized before the study database lock, and
359 will be performed using SAS version 9.4 (SAS Institute) and R version
360 4.4.0 or higher (R Foundation for Statistical Computing). The reporting
361 of trial results will conform to the Consolidated Standards of Reporting
362 Trials guidelines for randomized trials.

363 **Ethical considerations**

364 The study adheres to the ethical guidelines outlined in the
365 Declaration of Helsinki. The protocol was approved by the Ethics
366 Committee of the First Affiliated Hospital of the Army Medical
367 University and all participating centers. Any modifications to the trial

368 protocol will only be executed after obtaining further approval from the
369 ethics committee.

370 **Discussion**

371 Despite advancements in thrombectomy devices and workflow
372 processes, outcomes for patients with LVO remain suboptimal.
373 Adjunctive intra-arterial thrombolysis following successful reperfusion in
374 patients with LVO stroke has the potential to improve functional
375 outcomes, while the optimal dose remains unclear. To our knowledge, the
376 DATE trial is the first to evaluate the safety, efficacy, and dose-response
377 effects of intra-arterial tenecteplase in patients with LVO stroke after
378 successful EVT.

379 The CHOICE study demonstrated the potential benefits of
380 intra-arterial alteplase at a dose equivalent to 1/4 of the standard
381 intravenous thrombolytic dose for patients with acute ischemic stroke due
382 to LVO following successful recanalization.⁸ However, it did not conduct
383 a dose escalation exploratory trial, leaving the ideal dose that balances
384 efficacy and safety unknown.

385 Tenecteplase, a third-generation thrombolytic drug, has
386 demonstrated superiority over alteplase in improving excellent functional
387 outcomes and reducing disability at 3 months.¹⁹ There is an important
388 need to determine which dose provides the best balance of efficacy and
389 safety in patients with LVO following successful EVT. Current trials

390 such as POST-TNK²⁰ and ANGEL-TNK²¹ are exploring different doses
391 of intra-arterial tenecteplase in patients with acute ischemic stroke due to
392 LVO following successful EVT, using doses of 0.0625 mg/kg, 0.0625
393 mg/kg, and 0.125 mg/kg, respectively. However, the IA doses in these
394 trials were determined based on a similar fraction of the IV alteplase dose
395 used in CHOICE (one fourth) or were based on trial steering committee
396 recommendation, rather than dose-escalation study. Therefore, this study
397 will provide insight to characterize the optimal dose of adjunctive
398 intra-arterial tenecteplase administration in these patients.

399 The DATE trial enrolled its first patient on July 27, 2023, and as of
400 August 25, 2024 has enrolled 205 subjects. Full study completion
401 (including collection on 3-month outcomes) is expected by November
402 2024. When completed, this trial will provide pivotal data allowing
403 assessment of the optimal dose, safety, and efficacy of intra-arterial
404 tenecteplase in patients with acute ischemic stroke due to LVO following
405 successful EVT.

406 **Funding**

407 The project was supported by the Key Project of Chongqing Science
408 (2023ZDXM025), National Natural Science Foundation of China (No.
409 82425021), and Health Joint Medical Research Project and the Major
410 Project of Clinical Research Incubation at the First Affiliated Hospital of
411 Army Medical University (2023IITZD01).

412 **Conflicts of interest**

413 The author(s) declare the following potential conflicts of interest
414 with respect to the research, authorship, and/or publication of this article:

415 JLS reports consulting fees for advising on rigorous and safe clinical trial
416 design and conduct from Biogen, Boehringer Ingelheim, Genentech,
417 Johnson & Johnson, Phenox, Phillips, Rapid Medical, and Roche. TNN
418 discloses Associate Editor of Stroke, advisory board of Aruna Bio and,
419 Brainomix. RGN reports consulting fees for advisory roles with
420 Anaconda, Biogen, Cerenovus, Genentech, Philips, Hybernia, Hyperfine,
421 Imperative

422 Care, Medtronic, Phenox, Philips, Prolong Pharmaceuticals, Stryker
423 Neurovascular, Shanghai Wallaby, Synchron, and stock options for
424 advisory roles with Astrocyte, Brainomix, Cerebrotech, Ceretrieve,
425 Corindus Vascular Robotics, CrestecBio Inc., Euphrates Vascular, Inc.,
426 Vesalio, Viz-AI, RapidPulse and Perfuze. RGN is one of the Principal
427 Investigators of ENDOLOW trial. Funding for this project is provided by
428 Cerenovus. RGN is the Principal Investigator of the DUSK trial. Funding
429 for this project is provided by Stryker Neurovascular. RGN is an investor
430 in Viz-AI, Perfuze, Cerebrotech, Reist/Q'Apel Medical, Truvic, Tulavi
431 Therapeutics, Vastrax, Piraeus Medical, Brain4Care, Quantanosis AI, and
432 Viseon. T.Nguyen reports Associate Editor of Stroke; advisory board of
433 Brainomix, Aruna Bio; speaker for Genentech and Kaneka. Other

434 author(s) declare no potential conflicts of interest with respect to the
435 research, authorship, and/or publication of I article.

436 **Contributorship:**

437 ZZ, WZ, XH, DW, JLS, TNN, and RGN designed and
438 conceptualized the study. XH, JH, CG, YH, LW, LC, QL, JW, and MW
439 participated in data collection. XH, YH, JH, and CG wrote the manuscript.
440 All authors critically revised and approved the manuscript.

441 **Acknowledgement**

442 None.

443 **References**

- 444 1. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic
445 analysis for the Global Burden of Disease Study 2019. *The Lancet Neurology*.
446 2021;20(10):795-820.
- 447 2. Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the Early Management of Patients
448 With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management
449 of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart
450 Association/American Stroke Association. *Stroke*. 2019;50(12):e344-e418.
- 451 3. Goyal M, Menon B, van Zwam W, et al. Endovascular thrombectomy after large-vessel
452 ischaemic stroke: a meta-analysis of individual patient data from five randomised trials.
453 *Lancet (London, England)*. 2016;387(10029):1723-1731.
- 454 4. Liebeskind DS, Bracard S, Guillemin F, et al. eTICI reperfusion: defining success in
455 endovascular stroke therapy. *J Neurointerv Surg*. 2019;11(5):433-438.
- 456 5. Ng F, Churilov L, Yassi N, et al. Prevalence and Significance of Impaired Microvascular Tissue
457 Reperfusion Despite Macrovascular Angiographic Reperfusion (No-Reflow). *Neurology*.
458 2022;98(8):e790-e801.
- 459 6. Laredo C, Rodriguez A, Oleaga L, et al. Adjunct Thrombolysis Enhances Brain Reperfusion
460 following Successful Thrombectomy. *Ann Neurol*. 2022;92(5):860-870.
- 461 7. Jia M, Jin F, Li S, et al. No-reflow after stroke reperfusion therapy: An emerging phenomenon
462 to be explored. *CNS neuroscience & therapeutics*. 2024;30(2):e14631.
- 463 8. Renú A, Millán M, San Román L, et al. Effect of Intra-arterial Alteplase vs Placebo Following
464 Successful Thrombectomy on Functional Outcomes in Patients With Large Vessel Occlusion
465 Acute Ischemic Stroke: The CHOICE Randomized Clinical Trial. *Jama*. 2022;327(9):826-835.

- 466 9. Tsivgoulis G, Katsanos AH, Sandset EC, et al. Thrombolysis for acute ischaemic stroke: current
467 status and future perspectives. *The Lancet Neurology*. 2023;22(5):418-429.
- 468 10. Coutts SB, Berge E, Campbell BC, Muir KW, Parsons MW. Tenecteplase for the treatment of
469 acute ischemic stroke: A review of completed and ongoing randomized controlled trials.
470 *International journal of stroke : official journal of the International Stroke Society*.
471 2018;13(9):885-892.
- 472 11. Campbell BCV, Mitchell PJ, Churilov L, et al. Effect of Intravenous Tenecteplase Dose on
473 Cerebral Reperfusion Before Thrombectomy in Patients With Large Vessel Occlusion Ischemic
474 Stroke: The EXTEND-IA TNK Part 2 Randomized Clinical Trial. *Jama*. 2020;323(13):1257-1265.
- 475 12. Campbell BC, Mitchell PJ, Kleinig TJ, et al. Endovascular therapy for ischemic stroke with
476 perfusion-imaging selection. *N Engl J Med*. 2015;372(11):1009-1018.
- 477 13. Chan AW, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance
478 for protocols of clinical trials. *BMJ (Clinical research ed)*. 2013;346:e7586.
- 479 14. Zhang X, Xie Y, Wang H, et al. Symptomatic Intracranial Hemorrhage After Mechanical
480 Thrombectomy in Chinese Ischemic Stroke Patients: The ASIAN Score. *Stroke*.
481 2020;51(9):2690-2696.
- 482 15. Huang JH, Su QM, Yang J, et al. Sample sizes in dosage investigational clinical trials: a
483 systematic evaluation. *Drug design, development and therapy*. 2015;9:305-312.
- 484 16. Yuan Y, Hess KR, Hilsenbeck SG, Gilbert MR. Bayesian Optimal Interval Design: A Simple and
485 Well-Performing Design for Phase I Oncology Trials. *Clinical cancer research : an official
486 journal of the American Association for Cancer Research*. 2016;22(17):4291-4301.
- 487 17. Wang Y, Han S, Qin H, et al. Chinese Stroke Association guidelines for clinical management of
488 cerebrovascular disorders: executive summary and 2019 update of the management of
489 high-risk population. *Stroke and vascular neurology*. 2020;5(3):270-278.
- 490 18. Hernández-Jiménez M, Abad-Santos F, Cotgreave I, et al. Safety and Efficacy of ApTOLL in
491 Patients With Ischemic Stroke Undergoing Endovascular Treatment: A Phase 1/2 Randomized
492 Clinical Trial. *JAMA neurology*. 2023;80(8):779-788.
- 493 19. Palaodimou L, Katsanos AH, Turc G, et al. Tenecteplase vs Alteplase in Acute Ischemic Stroke
494 Within 4.5 Hours: A Systematic Review and Meta-Analysis of Randomized Trials. *Neurology*.
495 2024;103(9):e209903.
- 496 20. Jiacheng Huang CG, Jie Yang, Xiaolei Shi, Chang Liu, Jiaying Song, Fengli Li, Weilin Kong, Shitao
497 Fan, Zhouzhou Peng, Shihai Yang, Jinfu Ma, Xu Xu, Linyu Li, Zhixi Wang, Nizhen Yu, Wenzhe
498 Sun, Chengsong Yue, Xiang Liu, Dahong Yang, Cheng Huang, Duolao Wang, Raul G. Nogueira,
499 Thanh N. Nguyen, Jeffrey L. Saver, Yangmei Chen, Wenjie Zi. Adjunctive Intra-arterial
500 Tenecteplase after Successful Endovascular Thrombectomy in Patients with Large Vessel
501 Occlusion Stroke (POST-TNK): Study Rationale and Design. *European Stroke Journal*. 2024.
- 502 21. Huo X, Luo G, Sun D, et al. Intra-arterial tenecteplase after successful endovascular therapy
503 (ANGEL-TNK): protocol of a multicentre, open-label, blinded end-point, prospective,
504 randomised trial. *Stroke and vascular neurology*. 2024.

505

506

507

508 Figure 1. Flow chart for the Phase I of the DATE trial.

509

Dose level i

